In the News We’re proud to share that Dr. Gregory Vidal was recently featured in DocWire News. In this article, “Exploring the evERA BC Trial With Dr. Gregory Vidal: Improving Endocrine Response Beyond CDK4/6 Resistance,” Dr. Vidal discusses findings presented at ESMO 2025 from the phase 3 evERA BC trial—which investigated giredestrant plus everolimus in… Read more »